Abstract
Objective: to analyze the incidence of neutropenia in patients with colorectal cancer, undergoing chemotherapy treatment. Methods: integrative review performed in the following databases: National Library of Medicine, National Institutes of Health, Cumulative Index to Nursing and Allied Health Literature, Latin American literature and Caribbean Center in Health Sciences, and SciVerse Scopus. Results: 499 articles were identified, of which 15 met the criteria for inclusion, published between 2006 and 2016 and analyzed in their entirety. Neutropenia was the most reported hematologic toxicity in 12 (80.0%) studies, and the second most common in three (20.0%), in varying degrees, being responsible for reducing and/or delaying of doses in six (40.0%) studies. Conclusion: the studies included in this review showed that neutropenia in patients with colorectal cancer in chemotherapy treatment have low incidences in different degrees, despite the significantly high rates of neutropenia associations, as the most common adverse event in the various analyzed regimes.
Highlights
IntroductionThe chemotherapy treatment itself, and the oncological disease, determines multiplicity of clinical manifestations, which compromise, significantly, the health-related quality of life of patients affected by cancer[1,2,3]
The chemotherapy regimens used in the studies were 5-FU/LV, CAPOX or XELOX, XELIRI, FOLFIRI, FOLFOX, TEGAFIRI, FOLFOXIRI, Capecitabine monodrug and Irinotecan monodrug, combined or not with monoclonal antibodies. The results of this integrative review indicate that researches on the profile of toxicities, related to various chemotherapeutic regimens for treatment of colorectal cancer, still constitute a knowledge gap produced in Brazil
This review, due to the incidence of neutropenia revealed and its severity among the toxicities analyzed by the robust studies of the area, contributes to the importance of the knowledge about its relation with the prescribed chemotherapeutic regimens, as well as possible prophylactic actions and a reduction of damages with regards to nursing care given to patients with colorectal cancer
Summary
The chemotherapy treatment itself, and the oncological disease, determines multiplicity of clinical manifestations, which compromise, significantly, the health-related quality of life of patients affected by cancer[1,2,3]. Neutropenia is one of the hematological toxicities present in patients with colorectal cancer who receive chemotherapy treatment, it is one of the major risk factors in the complications of cancer patients. Due to not presenting symptoms, neutropenia is often detected during routine blood tests or tests for other conditions. For this and other reasons, patients undergoing chemotherapy, who are at higher risk for the condition, need to perform blood collection for laboratory tests on a regular basis[7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
